Solid Tumor Molecular Testing - Tissue Triage and Reporting

Key Points

• Confirm viable tumor and diagnosis before ordering molecular testing.
• Estimate tumor cellularity relative to the assay's validated limit of detection.
• Preserve tissue by prioritizing clinically necessary stains and tests.
• Choose DNA, RNA, FISH, IHC, or focused PCR according to the biomarker and tumor type.
• Decalcification and poor fixation can compromise nucleic acids.
• A negative molecular result is meaningful only within the assay's coverage and specimen adequacy.
• Clearly distinguish pathogenic/actionable variants from variants of uncertain significance.
• Tumor-only sequencing can suggest but cannot prove a germline variant.
• Negative plasma ctDNA does not exclude an actionable tumor alteration in a low-shedding cancer.
• Reports should describe clinically relevant assay limitations and specimen quality.

Algorithm

1. Define the clinical question and tumor-specific biomarker requirements.
2. Select the best available specimen and confirm tumor on a contemporaneous slide.
3. Estimate viable tumor fraction and macrodissect when appropriate.
4. Review fixation, decalcification, specimen age, and nucleic-acid quality.
5. Choose a validated assay capable of detecting the required alteration types.
6. Reserve tissue for complementary IHC, FISH, or confirmatory studies when needed.
7. Interpret variants using current evidence tiers and tumor context.
8. Flag potential germline findings for genetics referral according to policy.
9. If tissue testing is inadequate or impossible, consider validated plasma ctDNA when clinically appropriate.
10. Communicate actionable findings and major limitations clearly to the treating team.

Clinical Synopsis & Reasoning

Molecular tissue stewardship begins before sequencing. The pathologist identifies the specimen most likely to answer the clinical question, confirms that the block actually contains the target tumor, and estimates viable tumor fraction relative to the assay's validated limit of detection. Necrosis, fibrosis, inflammation, treatment effect, and normal tissue dilute tumor DNA and RNA. Macrodissection can enrich tumor when cellularity is borderline. Decalcification, especially strong-acid decalcification, can damage nucleic acids and should be avoided or documented when molecular testing is anticipated.

The correct assay depends on tumor type, stage, and the biomarker. Single-gene PCR can be efficient when one alteration drives a specific decision. Broad next-generation sequencing is favored when many actionable alterations, fusions, copy-number changes, or resistance mechanisms are relevant. RNA sequencing can improve fusion detection because DNA panels may miss large introns or complex rearrangements. FISH and immunohistochemistry remain valuable for selected amplifications, rearrangements, protein-expression biomarkers, and rapid triage. More testing is not automatically better; sequential low-yield stains and single-gene assays can exhaust a small biopsy before the most informative panel is ordered.

Preanalytic variables should be visible in the report. Formalin fixation time, specimen age, tumor percentage, extraction yield, nucleic-acid quality, and prior treatment can affect performance. A "negative" result is only as strong as the assay's coverage and sample adequacy. Reports should specify genes/regions interrogated, variant types detectable, key limitations, and whether low tumor content could reduce sensitivity. Variants of uncertain significance should be clearly separated from pathogenic or likely pathogenic alterations with established clinical actionability.

Germline implications require care. Tumor sequencing can reveal variants that may be inherited, but allele fraction alone cannot establish germline status. A finding in BRCA1/2, mismatch-repair genes, TP53, or another hereditary-cancer gene may prompt genetics referral depending on tumor type, variant, age, and clinical criteria. Conversely, absence of a variant on tumor-only testing does not always exclude germline disease.

Liquid biopsy can complement tissue when tissue is inadequate or unsafe to obtain, particularly in advanced cancers with sufficient circulating tumor DNA. A positive actionable plasma finding can be highly useful when validated, but a negative plasma assay can reflect low shedding and may require tissue testing. Clonal hematopoiesis can also generate plasma variants unrelated to the tumor, emphasizing the need for pathologic and genomic interpretation.

Treatment Strategy & Disposition

Molecular results should be translated into a ranked clinical interpretation rather than a list of mutations. Tiering systems identify alterations with established therapeutic, diagnostic, or prognostic significance, potential significance, or uncertain relevance. Oncologists then integrate the result with tumor histology, stage, prior therapies, comorbidities, regulatory approvals, guidelines, and clinical trials.

When tissue is limited, the laboratory should coordinate with the treating team before exhausting the block. Examples include preserving material for EGFR/ALK/ROS1 and broad sequencing in lung adenocarcinoma, HER2 and hormone-receptor testing in breast cancer, MMR/MSI testing in gastrointestinal cancers, and tumor-specific fusion or amplification assays. Re-biopsy is sometimes appropriate when the original specimen lacks viable tumor or when resistance biology has evolved.

Quality assurance includes orthogonal confirmation when required by assay validation or when an unexpected result has major consequences. Low-frequency variants near the assay limit, discordant histology, unusual gene-tumor combinations, or suspected sample contamination deserve review. Molecular tumor boards can help interpret complex findings and distinguish approved therapy from investigational hypotheses.

Epidemiology / Risk Factors

• The number of clinically actionable tumor biomarkers has expanded rapidly across solid tumors.
• Small biopsies and cytology specimens increasingly carry the entire diagnostic, staging, and molecular workload.
• Broad NGS reduces tissue consumption compared with long sequences of single-gene tests when many biomarkers are required.
• Plasma ctDNA use is increasing in advanced cancer but performance varies by tumor burden, site, and biology.
• Clonal hematopoiesis becomes more common with age and can complicate blood-based sequencing.

Investigations

Reporting Checklist

Pharmacology

Prognosis / Complications

• Prognostic value depends on tumor type and alteration; some variants are primarily predictive rather than prognostic.
• Identifying a high-confidence actionable driver can markedly improve outcomes when an effective targeted therapy exists.
• Poor specimen triage can delay treatment and force repeat biopsy.
• Accurate identification of resistance alterations can guide later-line therapy.
• Recognizing a potential hereditary variant can benefit both the patient and relatives after germline confirmation.

Patient Education / Counseling

• Explain that molecular testing looks for changes in the tumor that may guide treatment and is different from inherited genetic testing.
• Tell patients that a negative result does not mean the tumor has no mutations; it means no reportable alteration was found within the test's validated scope.
• Discuss why another biopsy or a blood-based assay might be needed if tissue is insufficient.
• Explain that a possible inherited finding from tumor testing requires a separate germline test.
• Encourage patients to retain the complete molecular report because future therapies and trial eligibility can change.

Notes

Tissue is a finite diagnostic resource. A pathology department's molecular workflow should make biomarker requirements visible at the moment a small biopsy arrives so the block is not consumed by repetitive immunostains before molecular testing is considered. Reflex testing can shorten time to treatment when the tumor type and stage justify it.

CAP cancer protocols and biomarker guidelines define many tumor-specific required elements, but no single universal solid-tumor panel fits every cancer. Current oncology practice increasingly uses broad testing in advanced disease while still preserving focused assays that have unique predictive value.

Reports should be updated when variant classification changes only according to laboratory policy and regulatory requirements. Clinicians should not assume that a five-year-old molecular interpretation remains current when new targeted therapies, resistance mechanisms, or classification standards have emerged.

References

1. College of American Pathologists Current Cancer Protocols and Biomarker Guidelines — Link
2. Association for Molecular Pathology Clinical Practice Guidelines — Link